Categories
Change Password!
Reset Password!
Type 2 diabetes (T2D) affects more than 30% of older adults and nearly 12% of the global population, making it one of the fastest-growing metabolic ailments worldwide.
GLP-1 RAs may lower the risk of Alzheimer’s disease, dementia, and overall neurodegenerative disorders in T2D patients compared with DPP-4i or basal insulin, supporting their potential neuroprotective benefit beyond glycemic control.
Type 2 diabetes (T2D) affects more than 30% of older adults and nearly 12% of the global population, making it one of the fastest-growing metabolic ailments worldwide. Beyond cardiovascular complications, T2D is increasingly recognized as a key risk factor for neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple dementia subtypes. However, robust evidence remains limited on whether specific glucose-lowering medications can reduce the long-term risk of neurodegeneration in T2D. This retrospective cohort study sought to fill this gap.
Investigators analyzed real-world data from the TriNetX global research network, comprising electronic health records of over 170 million individuals globally. Adults with T2D and no prior history of neurodegenerative disease who commenced either glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or dipeptidyl peptidase-4 inhibitors (DPP-4i) between 2010 and 2021 were identified.
Using 1:1 propensity score matching, treatment groups were balanced for baseline characteristics. A secondary analysis compared GLP-1 RA initiators with those starting basal insulin therapy. Subjects were followed for up to 5 years. The key endpoint was a composite outcome of incident neurodegenerative disorders, including:
For estimating hazard ratios (HRs), Cox proportional hazards regression models were utilized. Subgroup analyses were executed based on age, gender, and specific GLP-1 RA agents.
In a matched cohort of 214,442 individuals with T2D initiating GLP-1 RAs or DPP4i, 109,731 were females; the mean age was 58.6 years and the mean hemoglobin A1c (HbA1c) was 7.7%. Over a mean follow-up of 4.0 years, neurodegenerative disorders developed in 2,393 (2.2%) GLP-1 RA users versus 3,062 (2.9%) DPP4i users, corresponding to a hazard ratio (HR) of 0.81 and an absolute risk reduction of 0.6%.
Risk reduction was observed in women (HR 0.78) and men (HR 0.90), in those aged ≥65 years (HR 0.82) and <65 years (HR 0.84), and across specific agents including semaglutide (HR 0.75), liraglutide (HR 0.77), and dulaglutide (HR 0.82). Compared with DPP4i, GLP-1 RAs were linked with lower risks of dementia (HR 0.76), Alzheimer’s disease (HR 0.77), and vascular dementia (HR HR 0.75), while no prominent association was found for Parkinson’s disease (HR 1.04). Similar directional findings were noted when GLP-1 RAs were compared with basal insulin.
In this large multinational real-world study of patients with T2D, initiation of GLP-1 RAs was related to a considerably lower risk of new-onset neurodegenerative diseases, including Alzheimer’s disease and dementia, compared with DPP-4i or basal insulin.
These findings strengthen the hypothesis that GLP-1 RAs may have neuroprotective properties beyond glycemic control and highlight the urgent need for randomized trials to examine their role in dementia prevention and brain health in diabetes.
Cardiovascular Diabetology
Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study
Meir Schechter et al.
Comments (0)